MetaVia Inc., a clinical-stage biotechnology company, released its financial results for the first quarter ended March 31, 2025. The company reported a net loss of $3.7 million, compared to a net loss of $6.7 million for the same period in 2024. This translates to $0.36 per basic and diluted share, based on 10,264,202 weighted average shares outstanding, in contrast to $1.32 per share based on 5,089,408 weighted average shares outstanding in the previous year. Total operating expenses decreased significantly to $3.9 million from $6.9 million in the first quarter of 2024. This reduction was primarily due to a drop in research and development (R&D) expenses, which fell to $2.3 million from $4.9 million. General and administrative expenses also decreased to approximately $1.6 million from $2.0 million. MetaVia announced positive top-line results from its Phase 1 MAD trial for DA-1726 in obesity, showing promising weight loss, glucose control, and tolerability. The company plans additional cohorts to determine the maximum tolerated dose. Additionally, MetaVia successfully completed a private placement, generating $10 million in gross proceeds. With $11.2 million in cash at the end of the first quarter, and the additional funds from the private placement, the company expects to be funded into 2026.